Free Trial

Phreesia (NYSE:PHR) Insider Evan Roberts Sells 1,888 Shares

Phreesia logo with Medical background

Key Points

  • Insider Evan Roberts sold 1,888 shares of Phreesia stock for a total of $42,215.68, reducing his ownership by 0.26% to 724,949 shares.
  • Phreesia's stock is currently showing a modest increase, trading at $23.11, with a market cap of $1.38 billion.
  • The company reported a quarterly earnings per share (EPS) of $0.01, exceeding analyst estimates and showing a 14.9% increase in revenue compared to the same quarter last year.
  • MarketBeat previews top five stocks to own in November.

Phreesia, Inc. (NYSE:PHR - Get Free Report) insider Evan Roberts sold 1,888 shares of the firm's stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $22.36, for a total value of $42,215.68. Following the transaction, the insider owned 724,949 shares of the company's stock, valued at $16,209,859.64. This trade represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Evan Roberts also recently made the following trade(s):

  • On Tuesday, September 16th, Evan Roberts sold 3,761 shares of Phreesia stock. The shares were sold at an average price of $23.28, for a total value of $87,556.08.
  • On Thursday, August 28th, Evan Roberts sold 3,400 shares of Phreesia stock. The shares were sold at an average price of $32.46, for a total value of $110,364.00.
  • On Wednesday, August 27th, Evan Roberts sold 45,147 shares of Phreesia stock. The shares were sold at an average price of $32.02, for a total value of $1,445,606.94.

Phreesia Trading Up 0.7%

Phreesia stock traded up $0.17 during midday trading on Tuesday, reaching $23.11. 370,773 shares of the stock traded hands, compared to its average volume of 611,887. The company has a 50-day simple moving average of $26.02 and a two-hundred day simple moving average of $25.99. The company has a current ratio of 2.12, a quick ratio of 2.12 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.38 billion, a PE ratio of -55.02 and a beta of 0.68. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $32.76.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.08. The business had revenue of $117.26 million during the quarter, compared to analysts' expectations of $116.39 million. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The business's quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.03) EPS. Phreesia has set its FY 2026 guidance at EPS. Research analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Phreesia

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC grew its stake in Phreesia by 10,605.7% during the 1st quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock valued at $145,000 after purchasing an additional 5,621 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Phreesia in the 1st quarter worth approximately $462,000. QRG Capital Management Inc. lifted its holdings in shares of Phreesia by 8.0% in the 1st quarter. QRG Capital Management Inc. now owns 11,118 shares of the company's stock worth $284,000 after purchasing an additional 827 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new stake in Phreesia during the 1st quarter valued at $205,000. Finally, Bessemer Group Inc. raised its stake in Phreesia by 23.2% during the 1st quarter. Bessemer Group Inc. now owns 47,758 shares of the company's stock valued at $1,222,000 after acquiring an additional 8,978 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. JMP Securities lifted their price objective on Phreesia from $30.00 to $34.00 and gave the company a "market outperform" rating in a research note on Monday, September 8th. Raymond James Financial set a $33.00 target price on Phreesia and gave the company an "outperform" rating in a report on Friday, September 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Phreesia in a research note on Wednesday, October 8th. Truist Financial lifted their price target on Phreesia from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Friday, September 5th. Finally, Mizuho began coverage on Phreesia in a research note on Wednesday, August 27th. They issued an "outperform" rating and a $36.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $33.85.

View Our Latest Analysis on PHR

Phreesia Company Profile

(Get Free Report)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

Read More

Insider Buying and Selling by Quarter for Phreesia (NYSE:PHR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Phreesia Right Now?

Before you consider Phreesia, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.

While Phreesia currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.